drugset / Trial / NCT07568015

ReneuRx™ (Nerve Selective Therapy) Utilized in Lateral Hip Pain

NCT07568015

Not yet recruiting 100 enrolled Brixton Biosciences, Inc. MCRA · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

The goal of this clinical trial is to evaluate the safety and analgesic performance of the ReneuRx™ device in subjects with moderate to severe chronic lateral hip pain compared to subjects receiving treatment with corticosteroid injection in adults aged 22-80 years. Participants will attend study visits and complete quality of life questionnaires. Participants will be followed for approximately 6-12 months after the study procedure.

Timeline

Start
2026-07-01
Primary completion
2027-11-01
Completion
2029-11-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Triamcinolone Other / unclassified 40 mg Other

Indications

No indication recorded.